Cargando…
Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience
Nivolumab, a PD-1 checkpoint inhibitor, was approved in Canada in 2017 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the phase 3 trial CHECKMATE-141. We aimed to examine the demographics and efficacy of nivolumab in a Canadian, real-world set...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604932/ https://www.ncbi.nlm.nih.gov/pubmed/37887545 http://dx.doi.org/10.3390/curroncol30100645 |
_version_ | 1785126953004564480 |
---|---|
author | Du, Yue (Jennifer) Fu, Rui Levinsky, Justin T. Kamalraj, Pabiththa Chan, Kelvin K. W. Parmar, Ambica Eskander, Antoine Smoragiewicz, Martin |
author_facet | Du, Yue (Jennifer) Fu, Rui Levinsky, Justin T. Kamalraj, Pabiththa Chan, Kelvin K. W. Parmar, Ambica Eskander, Antoine Smoragiewicz, Martin |
author_sort | Du, Yue (Jennifer) |
collection | PubMed |
description | Nivolumab, a PD-1 checkpoint inhibitor, was approved in Canada in 2017 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the phase 3 trial CHECKMATE-141. We aimed to examine the demographics and efficacy of nivolumab in a Canadian, real-world setting. A retrospective chart review was performed on patients who received nivolumab for R/M HNSCC from 2017 to 2020 at a high-volume cancer centre. Data were abstracted from 34 patients, based on physician notes and imaging reports. The median patient age at nivolumab initiation was 61, 24% were female, and 62% were current or former smokers. Prior to nivolumab, 44% of patients underwent surgery, 97% radiation, and 100% chemotherapy. Most (97%) therapies were for primary disease. Overall survival at 6 and 12 months following drug initiation was 38% and 23%, respectively. Progression-free survival at 6 and 12 months was 33% and 22%, respectively. Eighteen percent of patients experienced an immune-related adverse event, the most common of which was pneumonitis (3/8) and endocrine events (3/8). Seven out of eight of the immune adverse events were grade 1–2; 1/8 was grade 3. Nivolumab appears to have decreased survival rates in our single-centre Canadian population compared to CHECKMATE-141 and presented a manageable adverse event profile for R/M HNSCC. |
format | Online Article Text |
id | pubmed-10604932 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106049322023-10-28 Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience Du, Yue (Jennifer) Fu, Rui Levinsky, Justin T. Kamalraj, Pabiththa Chan, Kelvin K. W. Parmar, Ambica Eskander, Antoine Smoragiewicz, Martin Curr Oncol Communication Nivolumab, a PD-1 checkpoint inhibitor, was approved in Canada in 2017 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the phase 3 trial CHECKMATE-141. We aimed to examine the demographics and efficacy of nivolumab in a Canadian, real-world setting. A retrospective chart review was performed on patients who received nivolumab for R/M HNSCC from 2017 to 2020 at a high-volume cancer centre. Data were abstracted from 34 patients, based on physician notes and imaging reports. The median patient age at nivolumab initiation was 61, 24% were female, and 62% were current or former smokers. Prior to nivolumab, 44% of patients underwent surgery, 97% radiation, and 100% chemotherapy. Most (97%) therapies were for primary disease. Overall survival at 6 and 12 months following drug initiation was 38% and 23%, respectively. Progression-free survival at 6 and 12 months was 33% and 22%, respectively. Eighteen percent of patients experienced an immune-related adverse event, the most common of which was pneumonitis (3/8) and endocrine events (3/8). Seven out of eight of the immune adverse events were grade 1–2; 1/8 was grade 3. Nivolumab appears to have decreased survival rates in our single-centre Canadian population compared to CHECKMATE-141 and presented a manageable adverse event profile for R/M HNSCC. MDPI 2023-09-29 /pmc/articles/PMC10604932/ /pubmed/37887545 http://dx.doi.org/10.3390/curroncol30100645 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Du, Yue (Jennifer) Fu, Rui Levinsky, Justin T. Kamalraj, Pabiththa Chan, Kelvin K. W. Parmar, Ambica Eskander, Antoine Smoragiewicz, Martin Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience |
title | Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience |
title_full | Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience |
title_fullStr | Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience |
title_full_unstemmed | Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience |
title_short | Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience |
title_sort | nivolumab for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective tertiary centre’s real-world experience |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604932/ https://www.ncbi.nlm.nih.gov/pubmed/37887545 http://dx.doi.org/10.3390/curroncol30100645 |
work_keys_str_mv | AT duyuejennifer nivolumabforrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivetertiarycentresrealworldexperience AT furui nivolumabforrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivetertiarycentresrealworldexperience AT levinskyjustint nivolumabforrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivetertiarycentresrealworldexperience AT kamalrajpabiththa nivolumabforrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivetertiarycentresrealworldexperience AT chankelvinkw nivolumabforrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivetertiarycentresrealworldexperience AT parmarambica nivolumabforrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivetertiarycentresrealworldexperience AT eskanderantoine nivolumabforrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivetertiarycentresrealworldexperience AT smoragiewiczmartin nivolumabforrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivetertiarycentresrealworldexperience |